Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia
Adductor Spasmodic Dysphonia, Abductor Spastic Dysphonia, Laryngeal Dystonia
About this trial
This is an interventional treatment trial for Adductor Spasmodic Dysphonia focused on measuring Adductor Spasmodic Dysphonia, Abductor Spastic Dysphonia, Laryngeal Dystonia, Vibtro-tactile stimulation
Eligibility Criteria
Inclusion Criteria:
- 18 years of age or older
- Confirmed diagnosis of adductor or abductor LD for a minimum of 6 months.
Exclusion Criteria:
- Regular intake of benzodiazepines
- Cognitive impairment: score < 27 on the Mini-mental State Examination (MMSE).
- Identify with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia other than LD, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis.
- Non-English speaker. We will not enroll people who cannot speak English, because the voice assessment procedures (Test sentences, CAPE_V clinical rating) have only been validated for English speakers at this point.
- Pregnant people. We will not enroll pregnant people as the device used in this study is investigational.
Sites / Locations
- University of Minnesota
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Low dose / continuous VTS
Low dose / speech activated VTS
High dose / continuous VTS
High dose / speech activated VTS
Low dose refers to receiving VTS 5 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
Low dose refers to receiving VTS 5 times/week for 20 minutes each; VTS during connected speech
High dose refers to receiving VTS 7 times/week for 20 minutes each; non-task-specific, constant stimulation during non-speech
High dose refers to receiving VTS 7 times/week for 20 minutes each; VTS during connected speech